Aim: To investigate the effects of leuprorelin using a self-administered quality-of-life (QOL) questionnaire in patients with recurrent gynecological cancer. Methods: Records of patients who received 3.75 mg leuprorelin every 4 weeks for the treatment of recurrent gynecological cancer were retrospectively reviewed. The physical domain of the QOL questionnaire, Care Notebook, was used to assess physical symptoms. Symptom deterioration was defined as a ≥10-point increase in baseline score; otherwise, symptoms were defined as controlled. Radiological and serological responses were evaluated according to the 2011 Gynecological Cancer Intergroup criteria. Results: From 2007 to 2015, 25 patients were administered leuprorelin for the treatment of epithelial ovarian cancer, granulosa cell tumor, endometrial cancer, endometrial stromal sarcoma and clear cell cervical cancer (in 13, 3, 6, 2 and 1 patients, respectively). Twenty patients had received a median of three lines (range 1-12 lines) of chemotherapy. Ten patients had progressive disease during their previous round of chemotherapy. Twenty patients completed the questionnaire every 4 weeks. Following leuprorelin treatment for 8 weeks, the symptom and disease control rates were 65% (13/20) and 44% (11/25), respectively. Two patients, one each with granulosa cell tumor and endometrial cancer, had stable disease at 6 months. Among the 20 patients who completed the QOL questionnaire, symptom control and disease control at 8 weeks showed a significant correlation (P = 0.016). Conclusion: Leuprorelin had minimal anticancer activity. The physical domain of the QOL questionnaire could be used to assess effects of hormonal treatment.
Introduction
Patients with late-stage cancer are administered chemotherapy to improve cancer-related symptoms and to maintain their quality of life (QOL). However, continuing chemotherapy may reduce QOL due to adverse events. These patients therefore require less toxic treatment.
Overexpression of receptors for luteinizing hormone-releasing hormone has been reported in ovarian and uterine neoplasms, with preclinical studies reporting that gonadotropin-releasing hormone (GnRH) analogs inhibited proliferation of these tumors. 1 GnRH agonists have been used traditionally to treat patients with relapsed epithelial ovarian cancer (EOC), granulosa cell tumor (GCT), endometrial cancer (EC) and low-grade endometrial stromal sarcoma (ESS). 2, 3 A randomized clinical trial of patients with EOC who experienced disease progression during or relapsed shortly after platinum-paclitaxel treatment showed similar survival during treatment with leuprorelin or treosulfan. 4 Of 15 patients with GCT, 6 (40%) patients demonstrated partial response (PR) after treatment with GnRH agonists. 5 Symptom relief is important during palliative cancer treatment. However, to our knowledge, no previous reports have evaluated QOL during treatment of recurrent gynecological cancer with GnRH analogs. We administered the self-administered QOL questionnaire, Care Notebook, in our daily oncologic practice starting in 2007. This retrospective study evaluated the effects of leuprorelin by radiological, serological and the QOL questionnaire assessment in patients with recurrent gynecological cancer.
Methods
This retrospective study included patients who received leuprorelin for recurrent gynecological cancer during the 2007-2015 period. Patients were subcutaneously administered 3.75 mg leuprorelin every 4 weeks until they experienced disease progression, unacceptable toxicity or until the patient discontinued for any other reasons. The physical symptoms were evaluated by measuring the physical domain score on the selfadministered Care Notebook QOL questionnaire at baseline and every 4 weeks after treatment with leuprorelin (http://www.care-notebook.com/en/index. html). 6 Care Notebook is composed of 10 items that assess physical well-being (Table 1) , six items that assess mental well-being and eight items that assess life well-being. Each item was scored from 0 (no complaints) to 10 points (worst complaint).
Care Notebook included open-ended questions, such as 'Please tell us how we might help you improve your health and life', which could be helpful for the healthcare team members responsible for the care of the patient. The physical domain score was calculated as the sum of points from 10 items, which ranged from 0 (no symptoms) to 100 points (worst symptoms). A difference of 10 points was considered clinically significant. 7 Symptom improvement was defined as a ≥10-point reduction in baseline score, whereas symptom deterioration was defined as a ≥10-point increase in baseline score or inability to administer the QOL questionnaire due to disease progression. Symptom stabilization was defined as neither symptom improvement nor deterioration. Physical symptom control was defined as the sum of symptom improvement and stabilization. Response was evaluated according to the 2011 Gynecological Cancer Intergroup (GCIG) criteria, which incorporated response evaluation criteria in solid tumors (RECIST), version 1.1, and serum cancer antigen 125 concentration. 8 Disease progression in patients with GCT was defined as a twofold or more increase in estradiol concentration compared with baseline. The disease control was defined as the sum of complete response (CR), PR and stable disease (SD). The physical symptom control rate (p-SCR) and disease control rate (DCR) were the percentages of patients who achieved physical symptom control and disease control at 8 weeks, respectively. The ratio of progression free survival (PFS) with leuprorelin to that with previous chemotherapy was calculated for patients with PFS longer than 8 weeks after leuprorelin administration. Overall survival (OS) was defined as the time from the first leuprorelin administration to death. All statistical analyses were performed using XLSTAT 2014 (Addinsoft). Collection of patient data was approved by the institutional review board at Hyogo College of Medicine. (Tables 2,3 ). Their median age was 62 years (range 26-82 years). Five patients had no previous history of chemotherapy, whereas the other 20 had received a median of three lines of previous chemotherapy (range 1-12 lines). Ten patients had progressive disease during previous chemotherapy. Of the 20 patients administered the QOL questionnaire, four (20%) showed improvement and nine (45%) showed stabilization of physical symptom at 8 weeks, making the p-SCR 65% (Table 4 ). According to 2011 GCIG criteria, no patient achieved CR or PR, but 11 (44%) of the 25 patients had SD at 8 weeks, making the DCR 44%. Among the 20 patients administered the QOL questionnaire, the symptom control assessed by the physical domain of QOL questionnaire and the radiologically and serologically evaluated disease control at 8 weeks was significantly associated (P = 0.016).
A representative case of a correlation among radiological, serological and the QOL questionnaire assessment is shown in Figure 1 . Patient 14 had recurrent GCT during anastrozole treatment. Soon after secondary debulking surgery, she had pelvic, liver and lymph node metastases, and was treated with leuprorelin. Patient 13 was diagnosed with recurrent low-grade serous (LGS) ovarian carcinoma after fertility preservation treatment. She had SD for 5 months of leuprorelin treatment. Then, she agreed to undergo debulking surgery. Two other patients, one with GCT (patient 16) and one with EC (patient 21), showed SD at 6 months, making the 6 month PFS rate 8% (2/24 evaluable patients). Of the eight patients with high-grade serous ovarian cancer, none had PFS of over 3 months. The anticancer activity of leuprorelin and prior chemotherapy was compared in 19 patients who received prior chemotherapy. Of the six patients with PFS on leuprorelin for longer than 2 months, four (patients 7, 11, 20 and 21) had an equal or longer PFS on leuprorelin than on the previous chemotherapy. Thus, leuprorelin showed favorable PFS in 21% (4/19) of patients treated with more than three lines of chemotherapy. The OS of patients with ovarian cancer was 13 months (95% confidence interval [CI] 7.7-18 months) and the OS of patients with EC was 9 months (95% CI 3-15 months).
Discussion
Assessing the efficacy of leuprorelin using a QOL questionnaire showed symptom control in 65% of patients with recurrent gynecological cancer. Because most patients with gynecological cancer have undergone primary surgery, including bilateral salpingo-oophorectomy, the toxicities of leuprorelin were minimal. However, one of the two patients who had undergone fertility-preserving surgery showed mild climacteric symptoms. The antitumor activity of leuprorelin was evaluated by measuring PFS at 6 months and by comparison with prior chemotherapy. Two patients, one each with GCT and EC, showed PFS of 22 and 6 months, respectively. Patient 13, with LGS ovarian cancer, had SD for 5 months and then underwent debulking surgery, suggesting that PFS in this patient may have been longer than 6 months. Two patients each with EOC and EC experienced equal or longer PFS on leuprorelin than on previous chemotherapy. These four patients had each received more than three lines of previous chemotherapy, suggesting that previous chemotherapy had low antitumor activity.
According to the recent National Comprehensive Cancer Network clinical practice guidelines for the treatment of ovarian neoplasms, 9 leuprorelin is considered acceptable for the treatment of EOC, especially for LGS and grade 1 endometrioid carcinomas as well as GCT. A single institutional study found that maintenance hormonal treatment resulted in longer median PFS than observation alone in patients with stage II-IV LGS carcinoma who had undergone primary surgery and chemotherapy (hazard ratio 0.44; P < 0.001). 10 Of the 70 patients in that study who received hormonal treatment, 39 (56%) were treated with letrozole and seven (10%) with leuprorelin. In another retrospective study for the treatment of relapsed high-grade ovarian cancer, the 3-month PFS rate was 56% among 54 patients treated with letrozole and 65% among 43 patients treated with tamoxifen.
11
A literature review of individual cases and small case series reported that 40% of patients with GCT responded to GnRH analogs and that the response rate to hormone therapy, including GnRH analogs, aromatase inhibitors and progestins, was 71%. 5 Another study, however, involving patients enrolled in the nationwide network and registry of histopathology in the Netherlands, reported a response rate to hormonal therapy of 18%. 12 The disease in patient 16 showed progression after leuprorelin treatment for 22 months, followed by treatment with letrozole for 45 months.
National Comprehensive Cancer Network clinical practice guidelines for patients with uterine neoplasm regard GnRH analogs as acceptable for the treatment of recurrent ESS (category 2B). 13 To the best of our knowledge, however, no patients with recurrent ESS who had undergone bilateral salpingo-oophorectomy experienced CR or PR following treatment with GnRH analog alone. In contrast, aromatase inhibitors have induced CR or PR in several patients.
14 Currently, we do not propose leuprorelin but propose letrozole for the treatment of recurrent ESS.
Leuprorelin was first administered to our patient with platinum-resistant ovarian cancer (PROC) in 2007, and a prospective clinical trial (UMIN000001 561) for the treatment of recurrent gynecological cancer started in 2009. We administered leuprorelin instead of letrozole, because only a small number of cases treated with letrozole were reported before 2009. A randomized phase 3 study using leuprorelin for the treatment of PROC was reported in 2002, 4 while aromatase inhibitors including letrozole for the treatment of ovarian cancer were reported in phase 2 trials. 11 In GCT, response to GnRH agonists has been reported since 1989, 15 while response to letrozole was first reported in 2009. 16 Leuprorelin showed a response rate of 28% in endometrial cancer in 1996. 17 In 1998, leuprorelin was reported to be effective for treatment of patients with low-grade ESS, 18 while five case reports using letrozole were published before 2009. 19 In this study, symptom control was evaluated by measuring the physical domain of QOL questionnaire, Care Notebook. There is no consensus regarding the appropriate QOL questionnaire for measuring patient-reported outcomes in patients with gynecological cancer. A translated version of the QOL questionnaire following the standard forward-and backtranslation procedure may sound somewhat Figure 1 Representative case of correlation among radiological, serological and quality-of-life (QOL) questionnaire assessment (Case 14). QOL physical score was calculated using physical domain of selfadministered QOL questionnaire Care Notebook. A 10-point increase in QOL physical score was defined as 'deteriorated'. In patients with granulosa cell tumor (GCT), disease progression was defined as a twofold or more increase in estradiol concentration compared with baseline. E2, estradiol concentration; PD, progressive disease; RECIST, response evaluation criteria in solid tumors; SD, stable disease.
unnatural, and contains some questions about unfamiliar customs. Care Notebook was developed in Japan, which provided an advantage for use in our daily practice. Each question is simple and based on a 0-10-point linear analog scale that can be easily completed by patients. Our oncologic outpatients filled out the questionnaire during the waiting time in the hospital, which helped physicians to better understand the symptoms and healthcare needs of patients and to improve communication. Two randomized control trials found that the use of a QOL questionnaire in daily oncologic practice improved patients' QOL. 20, 21 QOL assessment of hormonal treatment of gynecological cancer was previously reported in two clinical trials. In a phase 3 randomized study using the European Organization for Research and Treatment of Cancer (EORTC) QOL questionnaire (QLQ-C30 and QLQ-OV-28), chemotherapy deteriorated social functioning of patients with PROC at 8 weeks compared with tamoxifen, while other domains including physical symptoms showed no differences. 22 In a phase 2 study on anastrozole, baseline QOL was measured in 45 patients with PROC by using EORTC QLQ-C30. 23 The symptom control and disease control were significantly associated, results that are consistent with those of this study. Scoring the physical domain of the QOL questionnaire could be useful to evaluate effects of hormonal treatment.
This study had several limitations, including its small sample size and the use of a single QOL questionnaire. To the best of our knowledge, however, this study is the first report to assess QOL in patients with recurrent gynecological cancer who were treated with GnRH analogs. Because of its minimal toxicity and low cost, leuprorelin might be a treatment option for patients with recurrent gynecological cancer, and QOL questionnaire could be useful to evaluate the effects of hormonal treatment.
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